Biodesix (BDSX) director awarded RSUs and stock options on Form 4 filing

Rhea-AI Filing Summary

Biodesix director Matthew Strobeck reported new equity awards. On January 2, 2026, he received 6,804 restricted stock units (RSUs), each representing one share of Biodesix common stock. These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026 and some are deferred so the underlying shares will be delivered after his separation from service.

On the same date, he was also granted 6,354 stock options with an exercise price of $6.46 per share, vesting in four substantially equal installments on the same 2026 dates and expiring on January 1, 2036. All awards are generally subject to his continued service as a director.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Strobeck Matthew

(Last) (First) (Middle)

919 WEST DILLON RD

(Street)

LOUISVILLE CO 80027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIODESIX INC [ BDSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/02/2026		A		6,804		(2)	(2)	Common Stock	6,804	$0	6,804(3)	D
Stock Options (Right to Buy)	$6.46	01/02/2026		A		6,354		(4)	01/01/2036	Common Stock	6,354	$0	6,354	D

Explanation of Responses:

1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").

2. These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

3. Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.

4. This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.

	/s/ Robin H. Cowie as Attorney-in-Fact for Matthew Strobeck	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Biodesix (BDSX) disclose in this Form 4?

The Form 4 reports that director Matthew Strobeck received grants of 6,804 restricted stock units (RSUs) and 6,354 stock options in Biodesix common stock on January 2, 2026.

How many RSUs did Biodesix director Matthew Strobeck receive and how do they vest?

He received 6,804 RSUs, each for one share of Biodesix common stock. They vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally conditioned on his continued service.

What are the terms of the stock options granted to the Biodesix director?

Strobeck was granted 6,354 stock options on January 2, 2026 with an exercise price of $6.46 per share. The options vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026 and expire on January 1, 2036.

Are any of the Biodesix RSUs deferred until after service ends?

Yes. The filing notes that the 6,804 RSUs represent deferred RSUs, and the shares of common stock underlying them will be issued to Matthew Strobeck after his separation from service with Biodesix.

Does this Form 4 indicate whether the Biodesix awards were direct or indirect holdings?

The reported RSUs and stock options are shown as held with direct (D) ownership by Matthew Strobeck, with no separate indirect ownership entity disclosed.

What is Matthew Strobeck’s role at Biodesix in this Form 4?

In this filing, Matthew Strobeck is identified as a director of Biodesix and is not listed as an officer or 10% owner.